Search

Your search keyword '"Fisher, Michael J"' showing total 762 results

Search Constraints

Start Over You searched for: Author "Fisher, Michael J" Remove constraint Author: "Fisher, Michael J"
762 results on '"Fisher, Michael J"'

Search Results

151. 2016 CTF Conference on Neurofibromatosis Type 1, Neurofibromatosis Type 2 and Schwannomatosis

153. Abstract CT233: Treatment of neurofibromatosis type 1 (NF1)-related plexiform neurofibromas (PN) with cabozantinib (XL184): A Neurofibromatosis Clinical Trials Consortium Phase II trial

154. LGG-02. A PHASE II PROSPECTIVE TRIAL OF SELUMETINIB IN CHILDREN WITH RECURRENT/PROGRESSIVE PEDIATRIC LOW-GRADE GLIOMA (PLGG) WITH A FOCUS UPON OPTIC PATHWAY/HYPOTHALAMIC TUMORS AND VISUAL ACUITY OUTCOMES: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY, PBTC-029B

158. Integrating Demand-Side Resources into the Electric Grid: Economic and Environmental Considerations

160. Contract Law in Hong Kong

161. Orbital/Peri-Orbital Plexiform Neurofibromas in Children with Neurofibromatosis type 1: Multi-disciplinary Recommendations for Care

163. Reproducibility of cognitive endpoints in clinical trials: lessons from neurofibromatosis type 1.

164. NFM-07. SPRINT: PHASE II STUDY OF THE MEK 1/2 INHIBITOR SELUMETINIB (AZD6244, ARRY-142886) IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1 (NF1) AND INOPERABLE PLEXIFORM NEUROFIBROMAS (PN)

165. NFM-03. EFFECT OF NEUROFIBROMATOSIS TYPE 1 ON LONG-TERM HEALTH OUTCOMES IN ADULT SURVIVORS OF CHILDHOOD ASTROCYTOMA: A REPORT FROM THE CHILDHOOD CANCER SURVIVOR STUDY

166. Neurofibromatosis type 1 and risk of late outcomes after a primary tumor: A report from the Childhood Cancer Survivor Study.

167. Preliminary report of a multicenter, phase 2 study of bevacizumab in children and adults with neurofibromatosis 2 and progressive vestibular schwannomas: An NF Clinical Trials Consortium study.

168. SPRINT: Phase II study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

169. Patterns of family management for adolescent and young adult brain tumor survivors.

175. Solid rockets

176. Solid rockets

177. Pediatric low-grade gliomas: next biologically driven steps

178. TRTH-22. DEVELOPING RISK-BASED SELECTION CRITERIA FOR THE NEXT SIOP TRIAL OF “SIGHT-SAVING THERAPY” FOR CHILDREN WITH NF1-ASSOCIATED VISUAL PATHWAY GLIOMA (NF1-VPG) – A QUALITATIVE ANALYSIS OF A CONSENSUS SURVEY

181. Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee

184. Orbital/Periorbital Plexiform Neurofibromas in Children with Neurofibromatosis Type 1

185. Solid rockets

186. Activity of Selumetinib in Neurofibromatosis Type 1–Related Plexiform Neurofibromas

187. First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.

188. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.

189. Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.

194. Phase II Study of the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886) in children with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PN).

195. The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway

197. WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?

198. Correction to: Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials.

Catalog

Books, media, physical & digital resources